Case Report: Rituximab Achieves Durable Remission in Adult FSGS Rituximab produced sustained 5-year remission in a case of steroid- and CNI-dependent adult focal segmental glomerulosclerosis (FSGS).

#Rituximab may enable prolonged remission in adult focal segmental glomerulosclerosis (#FSGS) according to a case report of a 34-year-old woman with steroid and #CNI dependent disease who remained relapse-free for 5 years after a 2-dose regimen

Read more: https://bit.ly/4e68AtJ

#MedSky #RareSky

In patients with R/R follicular #lymphoma, treatment with the triplet combo of #tafasitamab, #lenalidomide, and #rituximab led to significantly improved PFS compared with the SOC combo of lenalidomide plus rituximab, at a median 22.4 months vs. 13.9: https://ow.ly/PSaT50YBgcw
#HemeSky

Let’s goooooo! #CIDP #rituximab #truxima #autoimmune #longcovid #MaskUp

Among patients with follicular #lymphoma, adding #epcoritamab to the SOC combo of #lenalidomide plus #rituximab outperformed lenalidomide plus rituximab alone, resulting in ORRs of 95% vs. 79%, as well as a lower risk of disease progression or death: https://ow.ly/652R50YrQeT
#HemeSky #MedSky

Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo Statement of Significance: Multiple recent studies have highlighted the immunosuppressive impact of MUC16/CA125 on antibodies immune effector function incl

Antibody Therapeutics (IF=4.5, Oxford University Press)
🔥🔥 Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo
academic.oup.com/abt/article/...
#ADCC #CDC #CD20 #MUC16 #CA125 #rituximab #CD16

~3 years ago, I was diagnosed with #CIDP, an #autoimmunedisorder I believe was triggered by #Covid (bsky.app/profile/jeff...). With regular #rituximab infusions, I’ve regained strength and function. I continue to #MaskUp. Stay safe, #covidaware folks! Don’t quit — you’re not alone! #longcovidmonth 😷

An Anaphylaxis Reaction from Rituximab in Between Shady Years My doctor and I had tried 10 or more immunosuppressants for my Lupus to no avail. Rituximab was next, but I had an anaphylaxis reaction to it.

" #Rituximab is a biological agent (derived from organic sources) that targets #BCells. It was 1st created to treat cancer, namely lymphoma..Now, it is often used off-label to treat other #medical conditions, such as treatment-resistant #Lupus.": buff.ly/6RFNWrx

#AutoimmuneDisease #ChronicIllness

Been met zwarte hardloopschoen (duh) op bed van de dagverpleging. Mijn funny fanny pack, Star Wars cap en kaartje van Nienke van Beau ;p erbij als gelukspoppetjes. <3

De superdosis prutnison én de rituximab zijn weer door het lijf gejaagd; versneld ditmaal en dat ging prima! Nog een uurtje spoelen en dan zijn we weer voor een half jaar voorzien… ✨🤞

#dagverpleging #rituximab #immunotherapie #NMOSD

FDA-Approved Therapies for NMOSD Superior to Rituximab and Off-Label Treatments FDA-approved NMOSD therapies such as inebilizumab and C5 inhibitors show better efficacy than rituximab or off-label treatments.

In patients with #NMOSD, specific therapies approved by the @fda.gov demonstrate superior efficacy and safety compared with #Rituximab and off-label treatments. Study in Neurology Neuroimmunology & Neuroinflammation.

Read more: https://bit.ly/4pCwEqb

#RareDisease #Neurology

kermit the frog is covering his mouth with his hand and the word anticipation is written on the bottom . Alt: kermit the frog is covering his mouth with his hand and the word anticipation is written on the bottom . Kermit ‘biting his nails’.

De vorige keer hoefden we alleen de labuitslagen af te wachten voor groen licht en toen was de 2e infusie al gepland nog voordat ik met mijn ogen kon knipperen. Nu is de uitslag al sinds 5 januari bekend, maar heb ik nog steeds niets gehoord… 🤞🥴

#NMOSDeesDolleDagboek #rituximab

A new study in Neurology examines the effectiveness of extended dosing intervals for rituximab in stable relapsing-remitting MS. The result: disease activity remained low even with annual administration. To the study:
www.neurology.org/doi/10.1212/...

#MS #Rituximab #Neurology #neuroskyence

Eine neue Studie in Neurology untersucht die Wirksamkeit verlängerter Dosisintervalle bei Rituximab in stabiler schubförmiger MS. Ergebnis: Auch bei jährlicher Gabe blieb die Krankheitsaktivität niedrig. Mehr dazu hier:
www.dgn.org/artikel/ritu...

#MS #Rituximab #Neurologie

Rituximab Treatment For Lupus - My Anaphylaxis Reaction Story

"So we decided to give #rituximab 1 more go & slotted another $10,000 into the #health poker machine. I checked myself into the #hospital & prepared to chill out as it transfused over the next 4 – 6 hours. And then it started...": buff.ly/Nod61PT

#MondayBlogs #ChronicPain

Rituximab and Treg Cells Starts a Phase IIΔ Trial In Youth At Risk Of Diabetes A new clinical trial is exploring whether two different immune therapies, used alone or in combination, can delay or prevent the onset of  T...

Another new blog. This research is being done in Poland. cureresearch4type1diabetes.blogspot.com/2026/01/ritu...
#t1d #type1diabetes #Rituximab #CellTherapy

Case Report: IgG4-Related Colitis Managed With Steroids and Rituximab A 34-year-old male patient with IgG4-related colitis was successfully managed with steroids and rituximab, without the need for colectomy.

A patient with #Colitis associated with immunoglobulin G4-related disease (#IgG4RD) was successfully managed with #Steroids and #Rituximab. Case report in @annalsofim.bsky.social Clinical Cases

Read more: https://bit.ly/3Kpw4hd

#RareDisease #MedTwitter #InternalMedicine

A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding #epcoritamab to #rituximab + #lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings. #ASH25

Learn more: www.mskcc.org/news/new-tri...

AbbVie Secures FDA Approval for Epcoritamab in Combination Therapy for Relapsed Follicular Lymphoma AbbVie has announced that their drug Epcoritamab in combination with rituximab and lenalidomide has received FDA approval for treating relapsed follicular lymphoma, showing significant results.

AbbVie Secures FDA Approval for Epcoritamab in Combination Therapy for Relapsed Follicular Lymphoma #United_States #Epcoritamab #North_Chicago #Rituximab #Lenalidomide

Voorlopig heb ik nu alleen nog de bloeddrukplaspil. 🤘 Volgende flinke doses drugs hoogstwaarschijnlijk weer in januari.

#methylprednisolon #rituximab

Trusten! ✨🌙

Pharmacokinetic Characterization of #Rituximab in Patients with Glomerular Diseases journals.lww.com/drug-monitor... #hvhebron #far #nefro #imm [Text complet]

#CARTcell therapy, which targets specific immune cells ( #Bcells), has shown promise in treating autoimmune diseases, including those causing brain inflammation. This was the 1st successful treatment after conventional therapies, such as steroids, plasma exchange & #rituximab, failed.

Early Intervention With Rituximab May Benefit Patients With New-Onset Generalized MG Based on the results of the RINOMAX trial, early intervention with rituximab treatment may benefit patients with new-onset MG.

Early treatment with #Rituximab may provide better outcomes for patients with new-onset generalized #MyastheniaGravis (MG), according to the long-term follow-up results of the #RINOMAX clinical trial published in the @europeanjournalofneurology.ean.org

Read more: https://bit.ly/47G1Krl

#MedSky

Rituximab to Eculizumab Switch Could Reduce NMOSD Hospitalizations Switching from rituximab to eculizumab as maintenance therapy for NMOSD may reduce the frequency and duration of hospitalizations.

Switching from #Rituximab to #Eculizumab as maintenance therapy for neuromyelitis optica spectrum disorder (#NMOSD) may reduce the frequency and duration of hospitalizations. Study in Neurology and Therapy.

Read here: https://bit.ly/3LKdPTL

#RareDisease #Neurology #MedSky #RareSky

Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome Published in Expert Opinion on Biological Therapy (Vol. 25, No. 5, 2025)

Gute Übersicht zum aktuellen Forschungsstand (04/2025) von Autoantikörper-gerichteten Therapien bei #LongCovid & #MECFS

Vergleich aktueller Erkenntnisse zu #Rituximab, #Efgartigimod, #Daratumumab, #Immunadsorption, #BC007 & #IVIG

Die Tabelle im Link bietet eine schnelle Übersicht der Ergebnisse.

An Anaphylaxis Reaction from Rituximab in Between Shady Years The medications we tried were not much use for Lupus and its comorbidities. Here's what an anaphylaxis reaction from Rituximab feels like.

"My #rheumatologist then suggested trying #rituximab — a new #biologic drug in #Singapore back then. I would only be the 7th patient in the hospital to try it & the side effects included death..It would also cost a ‘mere’ $10,000, with no guarantee of success.": buff.ly/c5iCU9y

#MondayBlogs #lupus

The first trial of #Rituximab plus #Lenalidomide in newly diagnosed #FollicularLymphoma in China identified PU.1 as a key regulator of PD-L1/4-1BBL signaling and highlighted dual PD-L1/4-1BB targeting as a promising treatment. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

AMP just published!
"Pure Red Cell Aplasia in Follicular Lymphoma with Bone Marrow Involvement and Isoniazid Exposure"

Full paper here:
www.actamedicaportuguesa.com/revista/inde...

#isoniazid #latenttuberculosis #drugtherapy #follicularlymphoma #pureredcellaplasia #rituximab #actamedicaportuguesa

"The purpose of this study was to evaluate adherence to CDC #pneumococcal #vaccination recommendations for patients with MS receiving #ocrelizumab or #rituximab at an #MS center in an academic medical center before and after a nursing intervention."

doi.org/10.7224/1537...

Infusion Day! Let’s go! #CIDP #autoimmune #rituximab #MaskUp

Early recognition and thorough testing are key for managing acquired angioedema and finding its root cause.

#AcquiredAngioedema #Angioedema #Lymphoma #ChronicIllness #Autoimmune #Spoonie #Swelling #PatientAdvocacy #Rituximab #BloodCancer #RareDisease #Complement #Awareness #BioNews #AngioedemaNews

🔴 #ERSCongress, #ILD of known causes. Serena Bellani, #Italia, analyse la cohorte #RECITAL sur la réponse au traitement par #rituximab et la déplétion en lymphocyte B chez les patients atteints de #PID liée à une #connectivite.
#OrphaLung
@filiere-fai2r.bsky.social